Citalam 5 mg (Tablet)

Unit Price: ৳ 7.00 (5 x 10: ৳ 350.00)

Strip Price: ৳ 70.00

Medicine Details

Orally administered selective serotonin reuptake inhibitor (SSRI)
Pure S-enantiomer of the racemic bicyclic phthalate derivative citalopram
At least 100 fold more potent than the R-enantiomer with respect to inhibition of 5-HT reuptake
No or very low affinity for serotonergic or other receptors including alpha- and beta-adrenergic Dopamine, Histamine, Muscarinic and benzodiazepine receptors

SSRI or related antidepressants should not be started until 2 weeks after stopping an MAOI

Contraindicated in patients with known hypersensitivity to Escitalopram or Citalopram or any of the inactive ingredients of the drug product
Concomitant use of escitalopram in patients taking monoamine oxidase/pimozide is contraindicated

Less sedating and have fewer antimuscarinic and cardiotoxic effects than tricyclic antidepressants
Gastrointestinal effects (dose-related and fairly common include nausea, vomiting, dyspepsia, abdominal pain, diarrhoea, constipation)
Anorexia with weight loss (increased appetite and weight gain also reported) and hypersensitivity reactions including rash, urticaria, angioedema, anaphylaxis, arthralgia, myalgia, and photosensitivity
Other side-effects include dry mouth, nervousness, anxiety, headache, insomnia, tremor, dizziness, asthenia, hallucinations, drowsiness, convulsions, galactorrhoea, sexual dysfunction, urinary retention, sweating, hypomania or mania, movement disorders and dyskinesias, visual disturbances

Consider potential risks and benefits of treatment when treating a pregnant woman during the third trimester
Excreted in human breast milk, decision whether to continue or discontinue nursing or Escitalopram therapy should take into account the risk of citalopram exposure for the infant and the benefits Escitalopram treatment for the mother

Used with caution in patients with epilepsy, concurrent electroconvulsive therapy, history of mania, cardiac disease, diabetes mellitus, angle-closure glaucoma, concomitant use of drugs that increase risk of bleeding, history of bleeding disorders, hepatic and renal impairment

Dosage adjustment is not necessary in patients with mild or moderate renal impairment
Caution is advised in patients with severely reduced renal function (CLCR less than 30 ml/min)
Initial dose of 5 mg daily for the first two weeks of treatment is recommended in patients with mild or moderate hepatic impairment
Caution and extra careful dose titration is advised in patients with severely reduced hepatic function
For patients who are known to be poor metabolisers with respect to CYP2C19, an initial dose of 5 mg daily during the first two weeks of treatment is recommended

Mainly related to the central nervous system such as dizziness, tremor, and agitation
Symptoms also include gastrointestinal system symptoms (nausea/vomiting), cardiovascular system symptoms (hypotension, tachycardia, QT interval prolongation, and arrhythmia), and electrolyte/fluid balance conditions (hypokalaemia, hyponatremia)